| P2093 | author name string | Yue-Ming Li | |
| | Douglas S Johnson | |
| | Christina J Crump | |
| P2860 | cites work | The Discovery of Pyridone and Pyridazone Heterocycles as γ-Secretase Modulators | Q39156383 |
| | β-arrestin 2 regulates Aβ generation and γ-secretase activity in Alzheimer's disease | Q39234405 |
| | Design and synthesis of a novel series of bicyclic heterocycles as potent γ-secretase modulators. | Q39339274 |
| | Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice | Q39398322 |
| | A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline | Q22251083 |
| | Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state | Q22254058 |
| | Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors | Q24294213 |
| | Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease | Q24298408 |
| | Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo | Q24315707 |
| | Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease | Q24316501 |
| | TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity | Q24321405 |
| | CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production | Q24523660 |
| | Presenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formation | Q24530721 |
| | NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo | Q24679444 |
| | The amyloid precursor protein: beyond amyloid | Q24680465 |
| | Potential use of γ-secretase modulators in the treatment of Alzheimer disease | Q27004876 |
| | The genetics of Alzheimer disease | Q27026166 |
| | The Amyloid Precursor Protein Has a Flexible Transmembrane Domain and Binds Cholesterol | Q27679405 |
| | Structure of a presenilin family intramembrane aspartate protease | Q27683614 |
| | Notch signaling: cell fate control and signal integration in development | Q27861061 |
| | Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1 | Q28139001 |
| | Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease | Q28140038 |
| | A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain | Q28141707 |
| | Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network | Q28143129 |
| | Murine notch homologs (N1-4) undergo presenilin-dependent proteolysis | Q28214246 |
| | Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics | Q28237347 |
| | Skeletal and CNS defects in Presenilin-1-deficient mice | Q28238795 |
| | Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease | Q28241772 |
| | Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs | Q28251387 |
| | Requirement of PEN-2 for stabilization of the presenilin N-/C-terminal fragment heterodimer within the gamma-secretase complex | Q28252335 |
| | Identification of distinct gamma-secretase complexes with different APH-1 variants | Q28274942 |
| | Candidate gene for the chromosome 1 familial Alzheimer's disease locus | Q28295424 |
| | Gamma-secretase complex assembly within the early secretory pathway | Q28297818 |
| | Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch | Q28346677 |
| | Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities | Q28506461 |
| | Erlin-2 is associated with active γ-secretase in brain and affects amyloid β-peptide production | Q28509121 |
| | Affinity pulldown of γ-secretase and associated proteins from human and rat brain | Q28569661 |
| | Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm | Q28585594 |
| | Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis | Q28594871 |
| | The canonical Notch signaling pathway: unfolding the activation mechanism | Q29547725 |
| | Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein | Q29547803 |
| | Notch1 functions as a tumor suppressor in mouse skin | Q29614987 |
| | Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity | Q29616491 |
| | Amyloid deposition as the central event in the aetiology of Alzheimer's disease | Q29619450 |
| | Clinical and biomarker changes in dominantly inherited Alzheimer's disease | Q29619940 |
| | Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. | Q33207923 |
| | Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion | Q33222653 |
| | Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. | Q33245678 |
| | GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. | Q33276402 |
| | Gender- and age-dependent gamma-secretase activity in mouse brain and its implication in sporadic Alzheimer disease | Q33427814 |
| | Modulation of gamma-secretase specificity using small molecule allosteric inhibitors | Q33515793 |
| | Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease | Q33687945 |
| | Beta-amyloid precursor protein mutants respond to gamma-secretase modulators | Q33885289 |
| | Characterization of an atypical gamma-secretase complex from hematopoietic origin | Q33892554 |
| | The initial substrate-binding site of gamma-secretase is located on presenilin near the active site | Q33927461 |
| | Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial | Q33988701 |
| | Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production | Q34030951 |
| | A common enzyme connects notch signaling and Alzheimer's disease | Q34088470 |
| | Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization | Q34093329 |
| | Presenilin is the molecular target of acidic γ-secretase modulators in living cells | Q34125419 |
| | PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. | Q34169736 |
| | Dual role of alpha-secretase cleavage in the regulation of gamma-secretase activity for amyloid production | Q34186656 |
| | Regulation of tyrosinase trafficking and processing by presenilins: partial loss of function by familial Alzheimer's disease mutation | Q34249792 |
| | The many substrates of presenilin/γ-secretase | Q37845036 |
| | Biology and pathophysiology of the amyloid precursor protein | Q37869935 |
| | γ-Secretase inhibitors and modulators for Alzheimer's disease | Q37961792 |
| | γ-Secretase modulator in Alzheimer's disease: shifting the end. | Q38019798 |
| | Novel γ-secretase enzyme modulators directly target presenilin protein | Q38795269 |
| | Optimization of a natural product-based class of γ-secretase modulators | Q48352840 |
| | Identification of two novel synaptic γ-secretase associated proteins that affect amyloid β-peptide levels without altering Notch processing | Q48557891 |
| | Deletion of presenilin 1 hydrophilic loop sequence leads to impaired gamma-secretase activity and exacerbated amyloid pathology. | Q48592298 |
| | Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein | Q48634030 |
| | Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer’s disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure | Q51770733 |
| | gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. | Q51776761 |
| | Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. | Q51808780 |
| | Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. | Q53276850 |
| | Sting of Alzheimer's failures offset by upcoming prevention trials. | Q53332313 |
| | Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. | Q53341822 |
| | Conversion of the LXR-agonist TO-901317--from inverse to normal modulation of gamma-secretase by addition of a carboxylic acid and a lipophilic anchor. | Q53532102 |
| | Divergent Synthesis of Multifunctional Molecular Probes To Elucidate the Enzyme Specificity of Dipeptidic γ-Secretase Inhibitors | Q56674083 |
| | Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors | Q74071559 |
| | Abeta40 protects non-toxic Abeta42 monomer from aggregation | Q80270099 |
| | Cyclic hydroxyamidines as amide isosteres: discovery of oxadiazolines and oxadiazines as potent and highly efficacious γ-secretase modulators in vivo | Q82584301 |
| | Alzheimer's research. Stopping Alzheimer's before it starts | Q84824173 |
| | Identification of novel γ-secretase-associated proteins in detergent-resistant membranes from brain | Q34252876 |
| | Activation and intrinsic γ-secretase activity of presenilin 1 | Q34410897 |
| | Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa | Q34498158 |
| | γ-secretase modulators and presenilin 1 mutants act differently on presenilin/γ-secretase function to cleave Aβ42 and Aβ43. | Q34537154 |
| | {gamma}-Secretase Substrate Concentration Modulates the Abeta42/Abeta40 Ratio: IMPLICATIONS FOR ALZHEIMER DISEASE. | Q34635580 |
| | Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. | Q34649758 |
| | Active gamma-secretase complexes contain only one of each component | Q34655171 |
| | Evidence that CD147 modulation of beta-amyloid (Abeta) levels is mediated by extracellular degradation of secreted Abeta | Q34656224 |
| | Substrate docking to γ-secretase allows access of γ-secretase modulators to an allosteric site | Q34696540 |
| | Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. | Q34919663 |
| | Not(ch) just development: Notch signalling in the adult brain | Q35175155 |
| | Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. | Q35237466 |
| | Dissociation between the processivity and total activity of γ-secretase: implications for the mechanism of Alzheimer's disease-causing presenilin mutations | Q35498267 |
| | Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid β peptide length: support for a sequential model of γ-secretase intramembrane proteolysis and regulation by the amyloid β precursor protein (APP) juxtamembrane re | Q35562694 |
| | Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein | Q35562828 |
| | The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism | Q35578655 |
| | Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1 | Q35626369 |
| | First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms | Q35874372 |
| | The mechanism of γ-Secretase dysfunction in familial Alzheimer disease | Q36000134 |
| | Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of γ-secretase | Q36006799 |
| | Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease | Q36081889 |
| | Second generation γ-secretase modulators exhibit different modulation of Notch β and Aβ production | Q36294856 |
| | Notch signalling in vertebrate neural development | Q36374960 |
| | The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation | Q36562023 |
| | Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice | Q36614269 |
| | β-arrestin1 regulates γ-secretase complex assembly and modulates amyloid-β pathology | Q36655033 |
| | γ-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin | Q36742200 |
| | Pen2 and presenilin-1 modulate the dynamic equilibrium of presenilin-1 and presenilin-2 gamma-secretase complexes | Q37075276 |
| | Substrate-targeting gamma-secretase modulators | Q37182828 |
| | Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease | Q37192883 |
| | Amyloid beta protein: Abeta40 inhibits Abeta42 oligomerization | Q37230015 |
| | gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease | Q37339100 |
| | γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs | Q37818108 |
| | Novel γ-secretase modulators: a review of patents from 2008 to 2010. | Q37828163 |
| | Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment | Q39451354 |
| | NSAID-derived γ-secretase modulation requires an acidic moiety on the carbazole scaffold. | Q39505969 |
| | Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator | Q39511082 |
| | Attenuated Abeta42 responses to low potency gamma-secretase modulators can be overcome for many pathogenic presenilin mutants by second-generation compounds | Q39584972 |
| | Synthesis and SAR Studies of Fused Oxadiazines as γ-Secretase Modulators for Treatment of Alzheimer's Disease | Q39735318 |
| | Piperidine-derived gamma-secretase modulators | Q39754696 |
| | Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators | Q39761474 |
| | The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity | Q39951771 |
| | Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation | Q40061988 |
| | Signal peptide peptidase and gamma-secretase share equivalent inhibitor binding pharmacology. | Q40068858 |
| | Piperidine acetic acid based γ-secretase modulators directly bind to Presenilin-1. | Q40109092 |
| | Pathological activity of familial Alzheimer's disease-associated mutant presenilin can be executed by six different gamma-secretase complexes | Q40121494 |
| | Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. | Q40241539 |
| | Intra- or intercomplex binding to the gamma-secretase enzyme. A model to differentiate inhibitor classes | Q40245326 |
| | Stereo-controlled synthesis of novel photoreactive gamma-secretase inhibitors | Q40278030 |
| | Secretion of the Notch-1 Abeta-like peptide during Notch signaling | Q40325565 |
| | Transition-state analogue gamma-secretase inhibitors stabilize a 900 kDa presenilin/nicastrin complex. | Q40447129 |
| | Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. | Q40472233 |
| | Aph-1 contributes to the stabilization and trafficking of the gamma-secretase complex through mechanisms involving intermolecular and intramolecular interactions. | Q40472890 |
| | Mutations in APP have independent effects on Abeta and CTFgamma generation | Q40506128 |
| | The presenilin proteins are components of multiple membrane-bound complexes that have different biological activities | Q40559975 |
| | The role of presenilin cofactors in the gamma-secretase complex | Q40661006 |
| | The C-terminus of the beta protein is critical in amyloidogenesis | Q40779575 |
| | New photolabeling and crosslinking methods | Q40835281 |
| | A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model | Q40841974 |
| | Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases | Q40845419 |
| | NSAID-based γ-secretase modulators do not bind to the amyloid-β polypeptide | Q40867620 |
| | Development of clickable active site-directed photoaffinity probes for γ-secretase | Q41856924 |
| | γ-Secretase Modulators: Can We Combine Potency with Safety? | Q42071699 |
| | Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase | Q42165242 |
| | BMS-708,163 targets presenilin and lacks notch-sparing activity | Q42426620 |
| | Dual roles of the transmembrane protein p23/TMP21 in the modulation of amyloid precursor protein metabolism | Q42806319 |
| | Nonspecificity of binding of gamma-secretase modulators to the amyloid precursor protein | Q42951812 |
| | Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs | Q42968955 |
| | An APP inhibitory domain containing the Flemish mutation residue modulates gamma-secretase activity for Abeta production | Q43198294 |
| | Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains | Q43259456 |
| | A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity | Q43793656 |
| | gamma-Secretase: characterization and implication for Alzheimer disease therapy | Q44241753 |
| | Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation | Q44362261 |
| | Reconstitution of gamma-secretase activity | Q44393107 |
| | In vitro characterization of the presenilin-dependent gamma-secretase complex using a novel affinity ligand. | Q44503633 |
| | Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation | Q45078363 |
| | Stereoselective synthesis of photoreactive peptidomimetic gamma-secretase inhibitors | Q45095870 |
| | Cerebrospinal fluid amyloid-β (Aβ) as an effect biomarker for brain Aβ lowering verified by quantitative preclinical analyses | Q45159397 |
| | A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators | Q45338642 |
| | Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aβ42 without affecting other Aβ pools | Q46109982 |
| | Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects. | Q46401913 |
| | Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial | Q46616657 |
| | Nicastrin functions as a gamma-secretase-substrate receptor | Q46646587 |
| | The amyloid precursor protein C-terminal fragment C100 occurs in monomeric and dimeric stable conformations and binds γ-secretase modulators | Q46772118 |
| | Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h | Q47581900 |
| | TASTPM Mice Expressing Amyloid Precursor Protein and Presenilin-1 Mutant Transgenes Are Sensitive to γ-Secretase Modulation and Amyloid-β<sub>42</sub> Lowering by GSM-10h | Q47584943 |
| | Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). | Q48092766 |
| | Abeta40 inhibits amyloid deposition in vivo. | Q48305645 |
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 3197-3216 | |
| P577 | publication date | 2013-05-02 | |
| P1433 | published in | Biochemistry | Q764876 |
| P1476 | title | Development and mechanism of γ-secretase modulators for Alzheimer's disease | |
| P478 | volume | 52 | |